- Home
- KALV vs ACDC Comparison
KALV vs ACDC Comparison
Compare KALV & ACDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- ACDC
- Stock Information
- Founded
- KALV N/A
- ACDC 2014
- Country
- KALV United States
- ACDC United States
- Employees
- KALV N/A
- ACDC N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- ACDC Oilfield Services/Equipment
- Sector
- KALV Health Care
- ACDC Energy
- Exchange
- KALV Nasdaq
- ACDC Nasdaq
- Market Cap
- KALV 651.3M
- ACDC 764.1M
- IPO Year
- KALV N/A
- ACDC 2022
- Fundamental
- Price
- KALV $12.92
- ACDC $8.21
- Analyst Decision
- KALV Strong Buy
- ACDC Hold
- Analyst Count
- KALV 8
- ACDC 5
- Target Price
- KALV $24.83
- ACDC $7.10
- AVG Volume (30 Days)
- KALV 498.7K
- ACDC 1.1M
- Earning Date
- KALV 07-10-2025
- ACDC 05-07-2025
- Dividend Yield
- KALV N/A
- ACDC N/A
- EPS Growth
- KALV N/A
- ACDC N/A
- EPS
- KALV N/A
- ACDC N/A
- Revenue
- KALV N/A
- ACDC $2,209,700,000.00
- Revenue This Year
- KALV N/A
- ACDC N/A
- Revenue Next Year
- KALV N/A
- ACDC $2.19
- P/E Ratio
- KALV N/A
- ACDC N/A
- Revenue Growth
- KALV N/A
- ACDC N/A
- 52 Week Low
- KALV $7.30
- ACDC $3.83
- 52 Week High
- KALV $15.50
- ACDC $9.69
- Technical
- Relative Strength Index (RSI)
- KALV 60.56
- ACDC 73.73
- Support Level
- KALV $11.11
- ACDC $6.28
- Resistance Level
- KALV $11.93
- ACDC $5.01
- Average True Range (ATR)
- KALV 0.60
- ACDC 0.62
- MACD
- KALV 0.05
- ACDC 0.28
- Stochastic Oscillator
- KALV 80.09
- ACDC 78.68
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
About ACDC ProFrac Holding Corp.
ProFrac Holding Corp is engaged in providing hydraulic fracturing, completion services, and other complementary products and services to upstream oil and gas companies engaged in the exploration and production of North American unconventional oil and natural gas resources. Its operations are focused in West Texas, East Texas/Louisiana, South Texas, Oklahoma, Uinta, and Appalachian. The company operates in three segments: Stimulation Services, Proppant Production, and Manufacturing. Stimulation services, which generate the majority of the revenue for the company operate a fleet of mobile hydraulic fracturing units and other auxiliary equipment that generates revenue by providing stimulation services.